Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
Sanofi Aventis has revamped operations at its sterile injectables plant in Le Trait, France, adding three new production units that double syringe making capacity and diversify its vaccine manufacturing capability.
Ahead of the “open house” at its facility in Monteriggioni, Siena, Italian machining specialist Marchesini spoke with in-PharmaTechnologist.com about the new plant and its role in the firm's offering to the drug industry.
Sanofi-Aventis' disposable insulin pen SoloStar has been launched
across the US for use with the company's 24-hour basal insulin
Lantus (insulin glargine), despite patent infringement claims
emanating from fellow insulin...
Despite numerous media reports of an impending patent infringement
suit, Sanofi-Aventis has yet to formally hear anything from
plaintiff Novo Nordisk, who claims the French firm's SoloStar
insulin pen violates patents covering...
US diabetics will soon have a new alternative to the predominant
needle and syringe method of administering insulin, now that the
Food and Drug Administration (FDA) has granted marketing approval
to Sanofi-Aventis' Lantus SoloStar.
French pharmaceutical company, Sanofi-Aventis, reported an increase
in sales for the fourth quarter with its vaccine business
continuing to impress. The company's performance precedes two
upcoming decisions later this year that...
Danish pharmaceutical company Novo Nordisk has filed a lawsuit
against France's Sanofi-Aventis, alleging that the latter has
infringed patent protection for an insulin injection system for
The creation of Sanofi-Aventis last year created a dent in its
second-quarter net profit as the French company looked to provide
good news to its investors. The drug maker managed to raise its
earnings target for the year and accelerated...
French chemicals company Rhodia, already facing two separate
investigations for alleged accounting irregularities and insider
trading, has become embroiled in further legal fights just as it
starts to lift itself out of financial...
News that B-MS has dropped out of an agreement to develop Basulin,
an improved formulation of insulin which was the subject of a $165
million deal - including $20 million upfront - between the two
companies last year.
Switzerland's Novartis has decided to withdraw from any
negotiations with Aventis over a possible merger, after official
discussions with the latter and fellow French-based company
Sanofi-Synthelabo got underway.
Switzerland's Novartis has confirmed that it is interested in
joining with Aventis, but will not proceed with a formal bid unless
the French government draws back from its hostile stance on a
link-up, reports Phil Taylor.
Aventis could hang on to its 15 per cent stake in chemicals company
Rhodia under the terms of a new agreement with the European
Commission. The company will instead sell off its 49 per cent stake
in Wacker Chemie over the next several...
Sanofi's hostile bid for larger French rival Aventis may have been
rejected, but there are a number of arguments in favour of a link,
according to analyst Nicole Lamble at market research firm